PLX038
3 clinical trials
2 abstracts
7 indications
Indication
Small Cell Lung CancerIndication
Extra-Pulmonary Small Cell CarcinomasIndication
BreastIndication
CancerIndication
GliomaIndication
MedulloblastomaIndication
EpendymomaClinical trial
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersStatus: Active (not recruiting), Estimated PCD: 2021-08-13
Abstract
TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.Org: Institut Curie, Saint Cloud, France, Hopital Privé des Cotes d'Armor, Paris and Saint-Cloud, Medical Oncology Department and D3i, Paris and Saint Cloud,
Abstract
Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer.Org: Mayo Clinic Cancer Center Research Office, Prolynx Inc.,
Clinical trial
A Phase II Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-08-19
Clinical trial
Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsStatus: Recruiting, Estimated PCD: 2028-11-14